2025-09-19 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the data provided. I'll break it down section by section, provide relevant numbers first, and then add some commentary.

## JNJ Stock Analysis (September 18, 2025)

**0) Executive Summary:**

Johnson & Johnson (JNJ) is a global healthcare giant focused on pharmaceuticals, medical devices, and consumer health products. The stock is currently underperforming the S&P 500 significantly, with concerning technical indicators and a recent negative price movement. Analyst opinions lean towards "Buy," but recent news is mixed, and financial data reveals fluctuating profitability metrics. A cautious approach is advised.

**1) Performance vs. S&P 500 (VOO):**

*   **JNJ Cumulative Return:** 29.16%
*   **VOO Cumulative Return:** 106.00%
*   **Absolute Divergence:** -74.4
*   **Relative Divergence:** 8.3 (on a scale where min divergence is 0 and max divergence is 100)

**Analysis:**

JNJ has significantly underperformed the S&P 500. The negative divergence highlights a substantial gap in returns. The relative divergence of 8.3 suggests that JNJ's underperformance is near the lower end of its historical range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha    | Beta | Cap(B) |
|------------|---------|-------|----------|------|--------|
| 2015-2017  | 28.0%   | 56.1% | -1.0%    | -0.0 | 336.5  |
| 2016-2018  | 8.0%    | 56.6% | -10.0%   | 0.0  | 310.8  |
| 2017-2019  | 18.0%   | 56.6% | -12.0%   | 0.7  | 351.3  |
| 2018-2020  | 12.0%   | 59.2% | -8.0%    | 0.3  | 379.0  |
| 2019-2021  | 32.0%   | 59.6% | -16.0%   | 0.2  | 412.0  |
| 2020-2022  | 7.0%    | 61.4% | 5.0%     | 0.2  | 425.4  |
| 2021-2023  | -15.0%  | 61.4% | -33.0%   | 0.4  | 377.5  |
| 2022-2024  | -35.0%  | 61.4% | -61.0%   | 0.3  | 348.3  |
| 2023-2025  | 2.0%    | 70.1% | -56.0%   | 0.2  | 419.4  |

**Analysis:**

*   **Alpha:** The consistently negative alpha values (except for 2020-2022) suggest that JNJ has generally underperformed its benchmark on a risk-adjusted basis during these periods. Recently (2022-2025), this underperformance has been more extreme.
*   **Beta:** The beta values, mostly close to zero, indicate that JNJ's price has not been strongly correlated with the overall market.
*   **CAGR:** The Compound Annual Growth Rate shows highly fluctuating performance. Recent years reflect significant declines.
*   **MDD:** The Maximum Drawdown is substantial across all periods, indicating high potential for losses from peak to trough.

**2) Recent Price Action:**

*   **Current Price:** 174.16
*   **Previous Close:** 177.2
*   **Change:** -1.72 (-0.97%)
*   **5-day Moving Average:** 176.656
*   **20-day Moving Average:** 177.3665
*   **60-day Moving Average:** 169.0843

**Analysis:**

The stock is trading below both its 5-day and 20-day moving averages, suggesting a short-term downtrend. The price drop from the previous close confirms this negative momentum. However, the price is above its 60-day moving average, indicating that the longer-term trend may still be positive, although weakening.

**3) Technical Indicators:**

*   **Market Risk Indicator (MRI):** 0.3324 (Low Risk)
*   **RSI:** 45.77
*   **PPO:** -0.4304
*   **Hybrid Signal:** cash_70%_Sell 0.3% of holdings
*   **Delta_Previous_Relative_Divergence (20-day):** -3.3 (Negative)
*   **Expected Return (%):** -365.6%

**Analysis:**

*   **MRI:** The Market Risk Indicator suggests a low-risk environment.
*   **RSI:** The RSI is below 50, suggesting that the stock is not overbought but also not oversold.
*   **PPO:** The negative PPO indicates that the short-term moving average is below the long-term moving average, confirming the downtrend.
*   **Hybrid Signal:** The hybrid signal suggests a cautious approach, recommending a high cash position and selling a small portion of holdings.
*   **Delta_Previous_Relative_Divergence:** The negative change in relative divergence indicates worsening underperformance.
*   **Expected Return:** The highly negative expected return is a major concern.

**The price change of -1.72 from the previous close is a notable negative movement**, further reinforcing the short-term bearish sentiment.

**4) Recent News & Significant Events:**

*   **[2025-09-18] J&J Expects Innovative Medicines Growth Despite Stelara LOE:** Focuses on future growth despite loss of exclusivity for a key drug.
*   **[2025-09-18] J&J and Protagonist’s oral plaque psoriasis drug bests BMS’ Sotyktu:** Positive news regarding a successful drug trial.
*   **[2025-09-18] J&J launches IVL device in Europe; Medtronic looks at pacing for more patients:** Expansion into the European market with a new medical device.
*   **[2025-09-17] Sector Update: Health Care Stocks Edge Higher Late Afternoon:** General positive sentiment for the healthcare sector.
*   **[2025-09-17] Bernstein Reiterates a Sell Rating on Genmab A/S (GMAB):** Negative rating for a competitor.
*   **[2025-09-17] Sector Update: Health Care Stocks Higher in Afternoon Trading:** More positive sentiment for the healthcare sector.

**Analysis:**

The news is mixed. While there's positive news regarding new drug developments and market expansion, the expectation of growth despite the Stelara LOE suggests potential challenges.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (2.25 on a scale of 1-5, with 1 being Strong Buy)
*   **Opinions:** 23
*   **Target Price (avg/high/low):** 177.90 / 200.00 / 155.00

**Analysis:**

Analysts generally have a positive outlook on JNJ, with a consensus "Buy" rating and an average target price slightly above the current price. However, the range of target prices is wide, indicating uncertainty.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-07-24 | 2.3  | 23.74 B$  |
| 2025-04-23 | 4.57 | 21.89 B$  |
| 2024-10-23 | 1.12 | 22.47 B$  |
| 2024-07-25 | 1.95 | 22.45 B$  |
| 2025-07-24 | 1.95 | 22.45 B$  |

**Analysis:**

*   **EPS:** The Earnings Per Share (EPS) has been volatile.
*   **Revenue:** Revenue shows some fluctuation but remains relatively stable.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $23.74B    | 67.87%        |
| 2025-03-31   | $21.89B    | 66.40%        |
| 2024-12-31   | $22.52B    | 68.35%        |
| 2024-09-30   | $22.47B    | 69.01%        |
| 2024-06-30   | $22.45B    | 69.40%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE      |
|--------------|------------|----------|
| 2025-06-30   | $78.47B    | 7.06%    |
| 2025-03-31   | $78.11B    | 14.08%   |
| 2024-12-31   | $71.49B    | 4.80%    |
| 2024-09-30   | $70.16B    | 3.84%    |
| 2024-06-30   | $71.54B    | 6.55%    |

**Analysis:**

*   **Revenue:** Revenue has shown an increase over the last year.
*   **Profit Margin:** Profit margins are relatively high but have seen some decline recently.
*   **Equity:** Equity has generally increased.
*   **ROE:** The Return on Equity (ROE) is quite volatile, suggesting inconsistent profitability.

**7) Overall Assessment:**

*   **Underperformance:** JNJ is significantly underperforming the S&P 500.
*   **Technicals:** Short-term technical indicators point to a downtrend.
*   **Financials:** Revenue is growing, but profitability metrics are fluctuating.
*   **News:** Recent news is a mix of positive and concerning developments.
*   **Analyst Sentiment:** Analysts have a generally positive outlook.
*   **Risk:** The MRI indicates low market risk but the negative expected return raises serious concerns specific to JNJ.

**Conclusion:**

Based on this analysis, JNJ appears to be facing some challenges. While analysts are generally positive, the underperformance against the S&P 500, negative technical indicators, and mixed news suggest caution. The highly negative expected return should be a major red flag for potential investors. The recommendation from the hybrid signal to hold a high cash position and sell a small portion of holdings seems prudent in the current environment.
